Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 Oct 24;2 Suppl 1(Suppl 1):S7.
doi: 10.1186/1475-2883-2-S1-S7.

Loa loa encephalopathy temporally related to ivermectin administration reported from onchocerciasis mass treatment programs from 1989 to 2001: implications for the future

Affiliations

Loa loa encephalopathy temporally related to ivermectin administration reported from onchocerciasis mass treatment programs from 1989 to 2001: implications for the future

Nana AY Twum-Danso. Filaria J. .

Abstract

Of the 207 Serious Adverse Events (SAEs) following treatment with Mectizan(R) (ivermectin, Merck, Sharpe & Dohme) that were reported from 1989 to 2001 through the passive SAE surveillance system required of all onchocerciasis mass treatment programs, 65 were cases of 'Probable' or 'Possible' Loa loa Encephalopathy temporally Related to treatment with Mectizan(R) (PLERM).A retrospective analysis of these 65 PLERM cases revealed that 97% were from southern Cameroon, 85% were male and 93% were being treated with ivermectin for the first time. The mean time to onset of symptoms was 1.7 days (95% CI: 1.3, 2.2) but the mean time to receiving medical attention after the onset of symptoms was 2.0 days (95% CI: 1.5, 2.6). Hospitalization was reported in 53 cases with a mean duration of 27.5 days (95% CI: 13.3, 41.6, n = 35). Clinical outcome was reported in 34 cases: 64.7% recovered fully, 11.8% had partial neurologic deficit and 23.5% died. For the 32 cases where quantitative L. loa data were reported, the arithmetic means with 95% confidence intervals were for 1) peripheral blood: pre-treatment - 164,250 mf/ml (79,537, 248,963; n = 4); post-treatment within 1 month - 3926 mf/ml (2,128, 5,725; n = 21) and within 5 to 6 months - 7800 mf/ml (3417, 12,183; n = 7); and for 2) cerebrospinal fluid: 32 mf/ml (7, 37; n = 10) within 1 month post-treatment.Pending further research on practical methods to exclude individuals with high intensity L. loa infection from onchocerciasis mass treatment programs, more emphasis should be placed on surveillance and monitoring to ensure early recognition, referral and management of SAEs, during the first 2 years when majority of the population is presumably naïve to ivermectin.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Geographical distribution of reported encephalopathic cases following mass treatment with ivermectin from 1989 to 2001 (as of August 31, 2002)
Figure 2
Figure 2
PLERM cases reported from onchocerciasis mass treatment programs from 1989 to 2001* *cases reported as of August 31, 2002; all cases were reported from southern Cameroon other than 1 from the Central African Republic in 1997 and 1 from southern Sudan in 2001

Similar articles

Cited by

References

    1. Goa KL, McTavish D, Clissold SP. Ivermectin: a review of its antifilarial activity, pharmacokinetic properties and clinical efficacy in onchocerciasis. Drugs. 1991;42:640–658. - PubMed
    1. World Health Organization Onchocerciasis and its control: report of a WHO Expert Committee on Onchocerciasis Control. Technical Report Series No. 852. Geneva World Health Organization. 1995. - PubMed
    1. Foege WH. 10 years of Mectizan®. Ann Trop Med Parasitol. 1998;92:S7–S10. - PubMed
    1. Benton B, Bump J, Seketeli A, Liese B. Partnership and promise: evolution of the African river-blindness campaigns. Ann Trop Med Parasitol. 2002;96:5–14. doi: 10.1179/000349802125000619. - DOI - PubMed
    1. Awadzi K, Dadzie KY, Shulz-Key H, Haddock DR, Gilles HM, Aziz MA. The chemotherapy of onchocerciasis X. An assessment of four single dose treatment regimens of MK-933 (ivermectin) in human onchocerciasis. Ann Trop Med Parasitol. 1985;79:63–78. - PubMed